The Discounted Cash Flow (DCF) valuation of HLS Therapeutics Inc (HLS.TO) is (13.32) CAD. With the latest stock price at 5.60 CAD, the upside of HLS Therapeutics Inc based on DCF is -336.2%.
Based on the latest price of 5.60 CAD and our DCF valuation, HLS Therapeutics Inc (HLS.TO) is a sell. selling HLS.TO stocks now will result in a potential gain of 336.2%.
Note: valuation result may not be accurate due to the low predictability of business.
| Range | Selected | |
| WACC / Discount Rate | 5.8% - 6.8% | 6.3% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (34.53) - (9.13) | (13.32) |
| Upside | -712.3% - -261.9% | -336.2% |